other material
confidence high
sentiment neutral
materiality 0.25
Aileron Therapeutics discloses license agreements, cash position, and Series X terms
Rein Therapeutics, Inc.
- Reports $19.9M cash as of Nov 30, 2023; expects to fund operations into Q4 2024.
- Assumed five license agreements from Lung acquisition: Taiho, UTHSCT, UT Austin, MUSC, Vivarta.
- Series X Preferred Stock: 4,707 shares + warrants for 2,353,500 shares; raised $18.4M.
- If stockholder approval not obtained, holders can require cash settlement on conversion.